camptothecin has been researched along with st 1968 in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beretta, G; Biasotti, B; Carenini, N; Carminati, P; Dallavalle, S; De Cesare, M; Ferrari, A; Gallo, G; Martinelli, R; Marzi, M; Merlini, L; Penco, S; Perego, P; Pisano, C; Pratesi, G; Tinti, MO; Zunino, F | 1 |
| Benedetti, V; Beretta, GL; Carminati, P; Dallavalle, S; De Cesare, M; Merlini, L; Penco, S; Pisano, C; Pratesi, G; Tinelli, S; Zunino, F | 1 |
| Aulicino, C; Benedetti, V; Bucci, F; Carminati, P; De Cesare, M; Foderà, R; Penco, S; Pisano, C; Vesci, L; Zuco, V; Zunino, F | 1 |
| Beretta, GL; Carminati, P; Dallavalle, S; De Cesare, M; Ferrara, FF; Foderà, R; Guglielmi, MB; Merlini, L; Morini, G; Orlandi, A; Penco, S; Pisano, C; Pratesi, G; Vesci, L; Zuco, V; Zunino, F | 1 |
| Bucci, F; Cincinelli, R; Croce, AC; Favini, E; Pisano, C; Supino, R; Tortoreto, M; Zuco, V; Zunino, F | 1 |
| Benedetti, V; Zuco, V; Zunino, F | 1 |
| Bucci, F; Castorina, M; Dal Pozzo, A; Esposito, E; Muzi, L; Ni, M; Penco, S; Pisano, C; Vesci, L | 1 |
| Bucci, F; Cassinelli, G; Cominetti, D; De Cesare, M; Di Francesco, AM; Lanzi, C; Meco, D; Orlandi, A; Passeri, D; Petrangolini, G; Pisano, C; Riccardi, R; Tortoreto, M; Zaffaroni, N; Zuco, V; Zunino, F | 1 |
| Beretta, GL; De Cesare, M; Perego, P; Zaffaroni, N; Zuco, V | 1 |
| Bucci, F; Cusano, G; Di Francesco, AM; Meco, D; Patriarca, V; Pierri, F; Pisano, C; Riccardi, R; Torella, AR | 1 |
| Cominetti, D; De Cesare, M; Lauricella, C; Pisano, C; Veronese, SM; Zaffaroni, N; Zuco, V; Zunino, F | 1 |
| Barbieri, P; Cresta, S; Delmonte, A; Fasolo, A; Gallerani, E; Gianni, L; Hess, D; Joerger, M; Pace, S; Sessa, C | 1 |
| Barbieri, P; Delmonte, A; Gallerani, E; Hess, D; Joerger, M; Pace, S; Sessa, C | 1 |
1 review(s) available for camptothecin and st 1968
| Article | Year |
|---|---|
Namitecan: a hydrophilic camptothecin with a promising preclinical profile.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Models, Molecular; Structure-Activity Relationship | 2012 |
2 trial(s) available for camptothecin and st 1968
| Article | Year |
|---|---|
Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Platelets; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Male; Middle Aged; Neutrophils; Topoisomerase I Inhibitors | 2015 |
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms | 2015 |
10 other study(ies) available for camptothecin and st 1968
| Article | Year |
|---|---|
Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Humans; Imines; Immunoblotting; Inhibitory Concentration 50; Mice; Mice, Nude; Quantitative Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; DNA Cleavage; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental | 2007 |
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Caspase 3; DNA Damage; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Female; Humans; Mice; Mice, Nude; Microbial Viability; Mutant Proteins; Saccharomyces cerevisiae; Topotecan; Xenograft Model Antitumor Assays | 2008 |
Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.
Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Topotecan; Xenograft Model Antitumor Assays | 2010 |
ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968.
Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; DNA-Binding Proteins; Female; Humans; Infrared Rays; Ovarian Neoplasms; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Ultraviolet Rays | 2010 |
Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Integrin alphaVbeta3; Ligands; Mice; Molecular Conformation; Oligopeptides; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2010 |
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemokine CCL2; Chemokine CXCL16; Chemokines, CXC; DNA Topoisomerases, Type I; Female; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Mice, Nude; Pyrroles; Receptors, Scavenger; Rhabdomyosarcoma; Sarcoma; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Cerebellar Neoplasms; Child; Comet Assay; DNA Damage; Drug Synergism; Humans; Irinotecan; Medulloblastoma; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Platinum Compounds; Xenograft Model Antitumor Assays | 2012 |
Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; DNA Copy Number Variations; Drug Synergism; ErbB Receptors; Gene Dosage; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2014 |